Scroll Back to Top
Event

Meet Fortrea at ESMO Congress 2025

17–21 October 2025
Berlin, Germany
Booth #3032

Fortrea is excited to participate in the European Society for Medical Oncology (ESMO) Congress 2025, a premier global event that brings together oncology professionals, researchers, and innovators from around the world.

Join us at Booth 3032 to explore how Fortrea is helping reshape the future of oncology through powerful clinical development strategies, deep therapeutic specialists, and patient-focused solutions. Whether you're advancing early-phase research or driving late-stage trials, our team is here to collaborate and support your goals.

Connect with our specialists at ESMO 2025 to discuss your pipeline, explore partnership opportunities, and discover how we’re accelerating progress in cancer care—together.

Our oncology specialists will be available to discuss solutions across high-impact domains:

  • Tumour-specific development (e.g., breast, lung, hematologic cancers)
  • Precision oncology & biomarker strategy
  • Complex trial designs (basket, umbrella, platform trials)
  • Advanced therapies (cell, gene, immuno-oncology)
  • Paediatric and rare oncology trials
  • DCT/hybrid trial enablement
  • Global patient access & site feasibility
  • Long-term survival follow-up & retention planning

Discover Our Oncology Capabilities : https://www.fortrea.com/therapeutics/oncology
See how Fortrea is driving innovation across oncology trials.

Interested in a 1:1 meeting with our experts? 
Fill out the Contact Us form at the bottom of the page to schedule a personalized discussion.

Senior Leadership team

Andrew Hegedus, Senior Vice President, Global Clinical Development, Fortrea Andrew Hegedus, MBA Chief Development Officer
Jim Bush, MBChB, PhD, MRCS, FFPM, GFMD Vice President and Global Head, Clinical Pharmacology Physicians, Fortrea Dr. Jim Bush, MBChB, PhD, MRCS, FFPM, GFMD Vice President and Global Head, Clinical Pharmacology Physicians

Medical team

Kamal Veer Saini, MBBS, MD, MRCP (UK), DM Executive Medical Director and Head of European Oncology Medical Team
Amanda Nogueira Amanda Nogueira Senior Medical Director Oncology Therapeutic Expertise
Laura Vidal Laura Vidal, MD Vice President and Therapeutic Strategy Lead for Oncology
Marcin Koziej, MD Medical Director
Olga Bodriagova, MD, PhD Medical Director
Paulina Czajka-Francuz Paulina Czajka-Francuz MD, PhD Associate Medical Director
María García Requesens, MD María García Requesens, MD Medical Director

Strategic Delivery & Growth team

Ken Morrison Kenneth Morrison, PhD, PMP Executive Director Strategic Delivery & Growth (Oncology)
Alexia Paire Alexia Paire Senior Director, Strategic Delivery & Growth

Delivery team

Anne Himmel Dr. Anne Himmel Senior Manager, Site Engagement and Partnership Delivery
Jill Drummond Jill Drummond Senior Delivery Director
Héctor Herrero Héctor Herrero, CPM, Msc Senior Director, Global Project Delivery, Oncology
Anita Dingemans, MSc, CPMP, PMP Anita Dingemans, MSc, CPMP, PMP Senior Delivery Director, Oncology
Marco Gonsalvi Marco Gonsalvi DevOps Lead
Leanne Walsh Leanne Walsh Director, Global Project Safety Delivery, Patient Safety Solutions

Consulting team

Carla Sterk Carla Sterk Executive Strategist, Product Development and Market Access Consulting

Medical Device & Diagnostics team

Sumitra Smith Sumitra Smith Director, Project Management

Featured Presentation

Title: Capivasertib plus fulvestrant as first- and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the Phase 3 CAPItello-291 trial

AuthorsAffiliation
Hope S RugoCity of Hope Comprehensive Cancer Center, Duarte, California, USA
Sibylle LoiblGBG Forschungs GmbH, Neu-Isenburg, Germany 
Goethe University, Frankfurt, Germany
 
Mafalda OliveiraMedical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain 
Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
 
Sacha J HowellThe Christie NHS Foundation Trust, Manchester, UK
Florence DalencInstitut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Toulouse, France
Javier CortésInternational Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain
IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain
Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain
Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
Medica Scientia Innovation Research (MEDSIR), Ridgewood (New Jersey, USA), Barcelona (Spain)
Henry L Gomez Instituto Nacional de Enfermedades Neoplásicas (INEN), Departamento de Oncología Médica, Lima, Peru 
Universidad Ricardo Palma, Lima, Peru
Xichun HuShanghai Cancer Center, Fudan University, Shanghai, China
Komal JhaveriMemorial Sloan Kettering Cancer Center, New York, New York, USA 
Institut de Recerca Biomèdica, Barcelona, SpainWeill Cornell Medical College, New York, New York, USA
Serafin Morales MurilloInstitut de Recerca Biomèdica, Barcelona, Spain
Zbigniew NoweckiThe Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Meena OkeraICON Cancer Centre, Adelaide, South Australia, Australia
Yeon Hee ParkSamsung Medical Center, Sungkunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea
Masakazu ToiAffiliation at the time the work was conducted: Kyoto University Hospital, Kyoto, Japan
Lyudmila ZhukovaLoginov Moscow Clinical Scientific Center, Moscow, Russia
Kamal S SainiFortrea Inc., Durham, North Carolina, USA
Ian WadsworthOncology R&D, AstraZeneca, Cambridge, UK
Marta FulfordOncology R&D, AstraZeneca, Warsaw, Poland
Vijay PrasadOncology R&D, AstraZeneca, Cambridge, UK
Nicholas C TurnerRoyal Marsden Hospital, Institute of Cancer Research, London, UK

We look forward to seeing you in Berlin!

https://maps.app.goo.gl/NxD4Yh8rukQU7VaQA